MedTrace Logo

A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma

NCT07333469 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-01-13

No results posted yet for this study

Summary

The study will consist of a Phase I dose-escalation and Phase IIa dose-expansion component. Phase I dose-escalation phase will establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D),and evaluate the preliminary antitumor activity of HX111.

Conditions

  • Solid Tumor and Lymphoma

Interventions

DRUG

HX111 for injection

HX111, 0.5-2.5mg/kg, once every 3 weeks

Sponsors & Collaborators

  • Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-19
Primary Completion
2028-01-19
Completion
2030-01-19

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07333469 on ClinicalTrials.gov